The development of effective chemotherapy for central nervous system tumors is hampered by the blood-brain barrier and by limited drug diffusion in the brain tissue. BAY 59-8862 is a new taxane analog that was selected and developed for its activity against tumors with a P-glycoprotein-mediated, multidrug-resistant phenotype. Because P-glycoprotein is implicated in limiting the access of drugs to central nervous system tumor targets, the objective of this study was to evaluate the ability of intravenously administered BAY 59-8862 to affect the growth of central nervous system tumors.
A novel taxane active against an orthotopically growing human glioma xenograft / D. Laccabue, M. Tortoreto, S. Veneroni, P. Perego, E. Scanziani, M. Zucchetti, M. Zaffaroni, M. D'Incalci, E. Bombardelli, F. Zunino, G. Pratesi. - In: CANCER. - ISSN 0008-543X. - 92:12(2001 Dec 15), pp. 3085-92-3092. [10.1002/1097-0142(20011215)92:12<3085::AID-CNCR10150>3.0.CO;2-S]
A novel taxane active against an orthotopically growing human glioma xenograft
E. Scanziani;
2001
Abstract
The development of effective chemotherapy for central nervous system tumors is hampered by the blood-brain barrier and by limited drug diffusion in the brain tissue. BAY 59-8862 is a new taxane analog that was selected and developed for its activity against tumors with a P-glycoprotein-mediated, multidrug-resistant phenotype. Because P-glycoprotein is implicated in limiting the access of drugs to central nervous system tumor targets, the objective of this study was to evaluate the ability of intravenously administered BAY 59-8862 to affect the growth of central nervous system tumors.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
